Track changes to
clinical trials

Compare enrollment, primary outcome wording and completion dates—with links to ClinicalTrials.gov.

Try:Alkermes, Inc.Arrowhead PharmaceuticalsAnnovis Bio Inc. Browse recent changes

Recorded changes,
before and after

Spend less time comparing records and more time on your research.

Planned enrollment

Before: 240 participants. After: 360 participants.

Primary outcome wording

Before: Response rate at 12 weeks. After: Response rate at 24 weeks.

Estimated primary completion

Before: September 2027. After: March 2028.

Research the company and see what changed

For biotech analysts, competitive intelligence teams and journalists.

See the edit, skip the digging

See additions and removals in one view, without piecing together old trial records.

Browse trials

Illustrative example: an outcome measure with removed words struck through and added words highlighted.

Keep up with companies you follow

Get their recorded trial changes in a weekly email digest, with links to each update.

Browse sponsors

Illustrative example: a weekly email listing one recorded change for each of three followed companies.

Back your work with the source

Open the ClinicalTrials.gov record to check a change and cite it in your research or reporting.

Data sources

Illustrative example: a recorded change shown with its trial ID, posting date and a link to the registry record.

Recent trial changes

1,718 trials · 379 sponsors in this database

Arrowhead Pharmaceuticals

Posted 20 Nov 2026

Study of ARO-APOC3 in Adults With Dyslipidemia · NCT05413135

Main study measure wording changed

Before: Measure: Number of Participants with Treatment-Emergent Adverse Events (TEAEs) Time frame: Through 24 months. After: Measure: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Description: An adverse event (AE) was defined as any untoward medical occurrence that developed or worsened in severity during the conduct of a clinical study and did not necessarily have a causal relationship to study drug. TEAEs were defined as AEs that started on or after the first dose date of study drug. A summary of all Serious Adverse Events (SAEs) and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section. Time frame: Baseline through Month 24.

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Browse all trials

Read the monthly change reports

On the FDA calendar

Review dates and FDA decisions, linked to primary sources.

22 Dec 2026

Lorundrostat

Announced review target · Mineralys Therapeutics Inc. (MLYS) · hypertension in combination with other antihypertensive drugs

Open original source

22 Dec 2026

Lorundrostat

Announced review target · Mineralys Therapeutics Inc. (MLYS) · treatment of hypertension in combination with other antihypertensive drugs

Open original source

Open FDA calendar

Companies with recent changes

Explore recorded changes for the trial sponsors and listed companies we cover.

Alkermes, Inc.

10 trials in this database · Latest change 20 Nov 2026

Annovis Bio Inc.

ANVS · 5 trials in this database · Latest change 19 Nov 2026

Browse all sponsors

How we collect and check the data

Coverage & methods · Data sources

Which trials are included?

Initial coverage focuses on company-sponsored Phase 2/3 drug trials linked to US-listed companies. We add coverage as we verify sources and company links. Counts on the site describe records in our database, not every trial or every company program.

How far back does the history go?

The original research archive contains 1,642 trials and 14,436 selected field versions. Those are archive counts, not current database totals. The archive saves selected fields from selected versions, so it can miss changes. Some primary outcome text was shortened to 300 characters by the research collector. Trial pages explain the available history. Older records are imported separately; opening a page does not fetch missing historical versions.

What does a recorded change tell me?

It tells you that a value or text in the trial record changed. It does not establish why it changed or whether the change matters scientifically or commercially. In a manual check of 30 flagged primary outcome edits, 19 were substantive and 11 were rewordings. We label unreviewed changes as text edits.

Which dates am I seeing?

A trial record can be submitted on one date and posted publicly on another. Change histories show the saved posting date when available. A trial’s completion date may still be an estimate. Company statistics describe only the trials we cover, not the company’s complete track record.

What is in the FDA calendar?

We publish events backed by source records and linked to companies and drugs we track. Sources include company filings with the US Securities and Exchange Commission (SEC), FDA drug and biologic approval publications, complete response letters and advisory committee notices. Records with uncertain matches or conflicting evidence stay unpublished. The calendar shows when sources were scanned; a completed scan does not mean we found every event in the market.

How are regulatory events checked?

AI-assisted checks compare possible events with the cited original source and the company or drug involved. Automated checks can make mistakes, so we provide the sources for you to inspect.

Trial updates,
delivered weekly.

Follow three companies free. Get their trial changes in one weekly email.

No account needed for the weekly email of FDA dates and trial changes.